What it sells
Patient-facing AI agents.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHealth system, payor and pharma/device executives (operations, patient engagement, access) who book a meeting.
Trigger: what makes them buy now?
Devices left unused, RPM non-transmission, churn and lost complaints; scarcity of clinical staff.
Workflow: what inputs become what output?
AI agent makes activation and onboarding calls, re-engages non-transmitting RPM patients, helps with cost/access, triages troubleshooting, captures structured complaints and escalates to clinicians.
Economics: what it saves and how it charges
ROI claim: protects RPM/therapy reimbursement and reduces churn; cites about 47% connect rate on hard-to-reach populations (Jul 2026).
Distribution: how it reaches customers
Demo-led ("Book A Meeting"); no self-serve pricing shown.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2025-11-03 | Series C | $126M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.